Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,838
  • Shares Outstanding, K 13,670
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,210 K
  • EBIT $ -3 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings $-0.06 on 04/07/25
  • Next Earnings Date 04/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +1,665,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8120 +6.65%
on 02/24/26
1.0600 -18.30%
on 02/10/26
-0.0739 (-7.86%)
since 02/06/26
3-Month
0.6801 +27.33%
on 12/31/25
1.1000 -21.27%
on 01/14/26
-0.3040 (-25.98%)
since 12/05/25
52-Week
0.6801 +27.33%
on 12/31/25
2.6000 -66.69%
on 06/12/25
-0.2919 (-25.21%)
since 03/06/25

Most Recent Stories

More News
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

CAMBRIDGE, Mass. , Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.2090 (+0.48%)
NRSN : 0.8660 (+1.38%)
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Strengthens Global IP Portfolio for PrimeC Through 2042

NRSN : 0.8660 (+1.38%)
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

CAMBRIDGE, Mass. , Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2090 (+0.48%)
NRSN : 0.8660 (+1.38%)
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026

NRSNW : 0.2090 (+0.48%)
NRSN : 0.8660 (+1.38%)
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026

NRSN : 0.8660 (+1.38%)
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2090 (+0.48%)
NRSN : 0.8660 (+1.38%)
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 0.8660 (+1.38%)
NeuroSense to Host Investor Webinar on December 8, 2025

Business, regulatory and clinical updates will be provided

NRSNW : 0.2090 (+0.48%)
NRSN : 0.8660 (+1.38%)
Neurosense Therapeutics Ltd. (NRSN) Receives a New Rating from Noble Financial

Neurosense Therapeutics Ltd. received a Buy rating and a $9.00 price target from Noble Financial analyst Robert LeBoyer on October 14. The company’s shares closed yesterday at $1.24.Elevate Your Investing...

NRSN : 0.8660 (+1.38%)
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Neurosense...

NRSN : 0.8660 (+1.38%)

Business Summary

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company. It focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease. NeuroSense Therapeutics Ltd. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.9625
2nd Resistance Point 0.9310
1st Resistance Point 0.8985
Last Price 0.8660
1st Support Level 0.8345
2nd Support Level 0.8030
3rd Support Level 0.7705

See More

52-Week High 2.6000
Fibonacci 61.8% 1.8666
Fibonacci 50% 1.6400
Fibonacci 38.2% 1.4135
Last Price 0.8660
52-Week Low 0.6801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar